insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

HLYK · Healthlynked Corp - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · HLYK

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue-$3.01M$5.72M$5.86M$9.20M$6.13M
Cost of Revenue------
Gross Profit------
R&D------
SG&A$2.04M$3.04M$3.62M$4.58M$4.93M$3.06M
Total Operating Expenses$4.18M$7.69M$9.87M$14.52M$14.24M$9.20M
D&A$101.9K$282.9K$352.0K$827.7K$827.7K$247.4K
Operating Income($2.11M)($4.68M)($4.15M)($8.66M)($5.04M)($3.07M)
Interest Expense--$0---
Income Tax------
Net Income($3.28M)($6.13M)($1.01M)($8.82M)($10.41M)($5.76M)
EPS - Basic($1.16)($2.00)$0.00($4.00)($5.00)($4.00)
EPS - Diluted($1.16)($2.00)$0.00($4.00)($5.00)($4.00)

Balance Sheet

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash & Equivalents$37.1K$76.2K$247.2K$61.9K$3.29M$162.2K
Accounts Receivable--$20.9K$72.3K$86.3K$87.2K
Inventory$18.0K$44.7K$133.2K$192.8K$134.9K$95.2K
Accounts Payable$530.7K$468.8K$251.5K$863.7K$361.3K-
Current Assets$1.55M$1.64M$656.2K$2.14M$3.65M$403.5K
Total Assets$1.70M$2.22M$4.28M$4.58M$10.69M$8.03M
Current Liabilities$7.01M$4.69M$2.41M$3.47M$1.92M$4.88M
Long-term Debt---$45.0K$17.9K-
Total Liabilities$7.46M$5.35M$3.48M$4.27M$3.49M$6.68M
Stockholders' Equity($5.76M)($3.13M)$804.7K$314.4K$7.20M$1.35M
Retained Earnings($50.54M)($48.16M)($42.03M)($41.02M)($32.21M)($21.78M)

Cash Flow

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Cash Flow($1.71M)($3.49M)($4.14M)($4.36M)($3.77M)($2.12M)
Investing Cash Flow$125.0K$422.4K$3.51M($544.8K)($341.4K)$1.81M
Financing Cash Flow$1.55M$2.90M$824.1K$1.68M$7.24M$356.8K
CapEx-$2.6K$1.5K$23.6K$19.3K$25.0K
Free Cash Flow-($3.50M)($4.15M)($4.39M)($3.79M)($2.14M)

Ratios

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Profitability
Gross margin------
Operating margin--155.5%-72.6%-147.8%-54.8%-50.1%
EBITDA margin--146.1%-66.4%-133.7%-45.8%-46.1%
Net margin--203.8%-17.7%-150.5%-113.2%-93.8%
Free cash flow margin--116.2%-72.5%-74.9%-41.2%-34.9%
FCF / Net income-0.574.100.500.360.37
R&D / Revenue------
SG&A / Revenue-101.0%63.3%78.1%53.6%49.9%
Effective tax rate------
Return on assets-192.7%-275.8%-23.6%-192.5%-97.4%-71.7%
Return on equity56.9%195.9%-125.8%-2803.5%-144.5%-426.3%
Return on invested capital------
Liquidity
Current ratio0.220.350.270.621.900.08
Quick ratio0.220.340.220.561.830.06
Cash ratio0.010.020.100.021.720.03
Leverage
Debt / Equity---0.140.00-
Debt / Assets---0.010.00-
Debt / EBITDA------
Interest coverage------
Equity multiplier-0.30-0.715.3214.571.485.95
Liabilities / Assets4.382.410.810.930.330.83
Efficiency
Asset turnover-1.351.341.280.860.76
Inventory turnover------
Days sales outstanding--1d5d3d5d
Days inventory outstanding------
Days payable outstanding------
Cash conversion cycle------
Valuation
P / E------
P / B--2515.5x5341.4x1492.9x1195.5x
P / S-196.5x353.7x286.7x1169.2x263.1x
EV / EBITDA------
Growth
Revenue growth (YoY)--47.4%-2.3%-36.3%50.0%-
Revenue CAGR (3y)--31.1%-2.3%---
Revenue CAGR (5y)------
Gross profit growth (YoY)------
Operating income growth (YoY)54.8%-12.7%52.1%-71.7%-64.2%4.3%
Net income growth (YoY)46.5%-505.8%88.5%15.3%-80.9%-4.1%
EPS growth (YoY)42.0%--20.0%-25.0%-6566.7%
EPS CAGR (3y)------
EPS CAGR (5y)------
FCF growth (YoY)-15.7%5.5%-15.8%-76.9%9.7%
FCF CAGR (5y)------
Book value growth (YoY)-84.1%-155.9%-95.6%433.6%-

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2024-12-31.

Business segments

$3.01M total
Health Services$2.87M · 95.5%
Medical Distribution$103.8K · 3.4%
Digital Healthcare$32.4K · 1.1%

Product / service

$5.91M total
Patent Service Revenue Net$2.87M · 48.6%
Patient Service Revenue Net$2.87M · 48.6%
Product Revenue$103.8K · 1.8%
Subscription And Event Revenue$32.4K · 0.5%
Subscription Revenue$32.4K · 0.5%

Stability scores

Piotroski F-score

FY 2025 · 9-point quality

3/9
Weak
  • ✗Net income positive
  • ✗Operating cash flow positive
  • ✓ROA improved YoY
  • ✓Cash flow > net income
  • -Long-term debt decreased
  • ✗Current ratio improved
  • ✓No share dilution
  • -Gross margin improved
  • -Asset turnover improved

Peer comparison

Same SIC group: Services-Offices & Clinics of Doctors of Medicine

CompanyRevenue (last FY)Net marginROE
HIMS$2.35B5.5%23.7%
TDOC$2.53B-7.9%-14.5%
TOI$502.73M-12.1%385.5%
LFMD$194.06M7.4%62.0%
CANO---

Comparing HealthLynked Corp against the 5 most active filers in the same SIC group.